CTXR Share Price Performance
US$0.76
-0.62 (-45.25%)
Price US$0.76
Share Pricen/a
Citius Pharmaceuticals, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 34 Fair Values set on narratives written by author
CTXR Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
No trending discussion available.
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Citius Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -1.69
- 77.34%
- -651.27%
- 8.4%
About CTXR
- Founded
- 2007
- Employees
- 23
- CEO
- WebsiteView website
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company’s late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
